Anthracyclines are a specific class of medications for adjuvant chemotherapy. They disrupt the enzymes (proteins that help chemical reactions in cells) that copy DNA during a cell’s life.

For decades, anthracyclines have been the gold standard of treatment for women with breast cancer, but that could be changing. Ever since Dennis J. Slamon, MD, director of clinical/translational ...

A retrospective analysis of four phase II trials and one phase III trial evaluated the prognostic impact of adjuvant anthracyclines on the efficacy of first-line epirubicin–paclitaxel regimens ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.

December 18, 2006 (San Antonio) — Anthracyclines have formed the backbone of adjuvant treatment for breast cancer, but new data presented at the 29th Annual San Antonio Breast Cancer (SABC ...

SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at San Antonio ...

Additionally, the benefits of anthracyclines in lower-risk patients (RS 26–30) may have been difficult to measure because of the overall lower risk of recurrence in this population.

However, because anthracyclines can rarely bring on serious and long-lasting side effects, including leukemia and/ or heart failure, some in the medical community wonder if we can eliminate them and ...

Anthracyclines disrupt tumor growth by binding to and blocking the function of topoisomerase II (TOP2). Topoisomerases break, twist, and reseal the phosphate backbone of DNA and, in so doing ...

Oncogene - Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms Skip to main content Thank you for visiting nature.com.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded.